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Abstract
During the 6th International Conference on Envenomation by Snakebites and Scorpion Stings in Africa held in Abidjan,
from 1 to 5 June 2015, the measures for the management of envenomation were discussed and new recommendations
were adopted by the participants. The high incidence and severity of this affliction were confirmed by several studies
conducted in African countries. The poor availability of antivenom, particularly because of the cost, was also highlighted.
Some experiences have been reported, mainly those regarding the financial support of antivenom in Burkina Faso (more
than 90 %) and Togo (up to 60 %) or the mandatory reporting of cases in Cameroon. Key recommendations concerned:
improvement of epidemiological information based on case collection; training of health workers in the management of
envenomation; policy to promote the use of effective and safe antivenom; and antivenom funding by sharing its
costs with stakeholders in order to improve antivenom accessibility for low-income patients.
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Introduction
Scorpion stings in North Africa and snakebites in sub-
Saharan Africa are responsible, respectively, for 750,000
cases of envenomation with 1,700 deaths, and 320,000
envenomations including ten thousands of deaths and
much debilitating sequelae [1, 2]. Envenomation usually
affects rural populations, generally young farmers whose
income is low. Household surveys found that almost all
victims of stings or bites by venomous animals were initially
assisted by a traditional healer – out of those, more than a
half were treated only by him – causing a consultation
delay, which was detrimental to the clinical course.
Organized jointly by the Société Africaine de Venimo-
logie – SAV (African Society of Venomology) and the
Pasteur Institute of Cote d’Ivoire, the 6th International
Conference on Envenomation by Snakebites and Scorpion
Stings in Africa (6ème Conférence Internationale sur les
Envenimations par Morsures de Serpent et Piqûres de
Scorpions en Afrique) was held from 1 to 5 June 2015
at the Faculty of Medical Sciences, University Félix
Houphouët-Boigny, in Abidjan, Côte d’Ivoire. As in previ-
ous meetings, this conference consisted of three different
sessions: a two-day workshop on the management of
envenomation; the scientific conference, which also ex-
tended over two days; and stakeholder meeting to discuss
the availability of antivenoms (www.sav-asv.com/).
Workshop on the management of envenomation
The first day of training involved forty trainers, mainly
Ivoirians, to whom the methodological basis of venomol-
ogy was presented (herpetology, epidemiology, biochem-
istry and toxicology of venoms, clinical manifestations
and treatment of envenomation) in order to clarify the
causes and consequences of the encounter between a
human and a venomous animal.
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The second day was dedicated to trainees and people that
deal with envenomation: physicians, pharmacists, nurses,
firefighters, rescue workers, paramedics and traditional
healers. Over 200 people attended the course that ex-
plained about the circumstances, symptoms and treatment
of snakebite in Côte d’Ivoire. The different clinical presen-
tations, as well as the therapeutic approach have been
described. A simple diagnostic and treatment algorithm
was presented.
Scientific conference
This session brought together about 200 participants from
18 countries from all continents (Germany, Belgium,
Benin, Burkina Faso, Cameroon, Côte d’Ivoire, France,
Ghana, Guinea, India, Kenya, Mali, Mexico, Morocco,
Nigeria, Senegal, Switzerland, and Togo). Representatives
of several countries, already registered (Algeria, Angola,
Brazil, Congo, Democratic Congo, USA, Great Britain, Italy,
Mauritania, Niger, Chad, Tunisia), could not attend, be-
cause unavailable or, most often, due to financial reasons.
In his inaugural lecture, Prof Abdulrazaq Habib pre-
sented an economic model showing the particularly profit-
able cost-benefit relation of antivenom use. Despite its
high cost, the burden for public finances and society are
greater when antivenom is not used taking into account
the reduction of life expectancy, disability-adjusted life
year (DALY) and quality-adjusted life year (QALY). The
costs per DALY and averted deaths vary, respectively, from
US$ 2,000 to US$ 6,000 and from US$ 100 to US$ 300,
depending on the country.
Most studies confirmed the high incidence and severity
of envenomation, and serious management deficiencies
related in particular to late consultation, inaccessibility of
antivenom and lack of training of medical personnel.
Various communications dealt with the diagnosis of en-
venomation and treatment either by antivenom or herbal
medicine. Overall, the availability of antivenom is inad-
equate, which was observed in most countries.
In this minicollection “Strategies for Management of
Snakebites in Africa”, four studies selected among those
presented at the conference are to be published in the
Journal of Venomous Animals and Toxins including
Tropical Diseases (JVATiTD):
 A research indicates that although the number of
reported victims of scorpions stings is elevated in
Morocco, snakebites also comprise a public health
problem in the country that affects several hundreds of
people, including some severe envenomation cases [3].
 Another study reports that in the region of
Kedougou (eastern Senegal), the annual incidence is
about 315 snakebites per 100,000 population.
Mortality exceeds eight deaths per 100,000
inhabitants according to household surveys,
whereas official health statistics reports less than a
third of those [4].
 In Burkina Faso, more than 35,000 envenomation
cases are notified annually with an average of 275
deaths. Despite these high numbers, a study reveals
that only 1,150 doses of antivenom are administered
every year in the region [5]. Therefore, although
antivenom is imported from neighboring countries,
the therapeutic coverage is far from enough.
 The other work revealed that in Benin,
ultrasonography comprises a valuable tool that helps
in the diagnosis and management of hemorrhagic
disorders provoked by Echis ocellatus bites that
represent more than 70 % of envenomation cases in
savannas of sub-Saharan Africa [6].
During the general assembly of the African Society
of Venomology, the creation of national subsidiaries –
designed to relay the recommendations of SAV and fa-
cilitate their implementation –that favor management
autonomy was unanimously approved.
Stakeholders meeting
On the last day, an open discussion was held among
stakeholders who were willing to participate. Once again,
with the notable exception of the 4th Conference in Dakar,
in which the World Health Organization (WHO) was
represented, international agencies, albeit invited, did
not attend.
The experiences of several represented countries were
exposed. Burkina Faso subsidizes antivenom price (up to
90 %), causing the retail price to be 2,500 FCFA (about
US$ 5). Since the beginning of 2015, Cameroon intro-
duced mandatory reporting of envenomation, as recom-
mended by WHO. Senegal forced every pharmacy in the
country to stock permanently at least one vial of anti-
venom. Togo has been supporting for five years the price
of antivenom by 60 % in the public drug distribution
system. Finally, Côte d’Ivoire has introduced the treatment
of envenomation in the National Program of Universal
Health Coverage that would be active by the end of 2015.
Following the debates, four major recommendations
were unanimously adopted.
Recommendations
1. Epidemiological studies should be performed to
assess the therapeutic needs, particularly the amount
of antivenom required and where it should be
available. Health authorities in each country were
encouraged to establish, as soon as possible, the
mandatory reporting of envenomation.
2. Training in the management of envenomation
should be restored rapidly in medical, pharmacy,
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and nurse schools. Meanwhile, training of health
personnel in the diagnosis of envenomation and
use of antivenoms should be organized within
each country.
3. Drug policy for antivenoms should be adapted to
the national context. Antivenom selection and
registration require rigorous criteria. Antivenoms are
complex biological products – antibodies produced
by horses – which cannot be manufactured as
generics. They require the use of venoms from local
species, whose traceability should be guaranteed.
Immunoglobulin purification and fragmentation
should be performed using delicate processes,
complying with standards set by WHO [7], and
the application of quality control at every stage.
The safety of antivenom should be favored as well
as its effectiveness, especially since it is used in
peripheral health centers, often poorly equipped
and supplied. These characteristics explain the
high price of antivenoms.
4. The accessibility of antivenoms should be ensured
through appropriate funding, defined after
anthropological investigations on the acceptability of
the price by the affected population. An equalization
of antivenom costs will involve the state budget,
support from local governments, companies
employing workers at risk (such as agribusiness
corporations), and health insurance groups that are
beginning to work in Africa.
Representatives from each country made a commitment
to convey these recommendations to national health au-
thorities and put in place the measures needed to achieve
them before the next international conference on en-
venomation in Africa, which should happen in 2018.
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